Jung Dao, MD
Ophthalmology · Phoenix, AZNPI 1427007202
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,243 of the $7,409 with a category attached, or 97.8%. Bausch Health US, LLC accounts for 97.8% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $7,243 and has fallen 98.3% since, to $122 in 2024.
Across 6 payments — averaging $1234.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch Health US, LLC$7K
- Dompe US, Inc.$122
- Novartis$32
- Biotissue Holdings Inc.$12
Across 22 payments — averaging $14,421 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$205K
- Bausch & Lomb Americas Inc.$65K
- Mallinckrodt Hospital Products Inc.$31K
- Aerie Pharmaceuticals, Inc.$17K
- AbbVie$53
What the payments were for
- Consulting fees$7,24398%
- Food & beverage$1662%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch Health US, LLC | 2 | $7,243 |
| Dompe US, Inc. | 1 | $122 |
| Novartis | 2 | $32 |
| Biotissue Holdings Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,409 in reported general payments places this provider in the 85th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pred FortePrednisolone Acetate | 80 | $16,731 |
| LumiganBimatoprost | 28 | $9,765 |
| Prednisolone Acetate | 212 | $8,407 |
| Alphagan PBrimonidine Tartrate | 30 | $5,629 |
| Difluprednate | 33 | $4,525 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 36 | $4,376 |
| MoxifloxacinMoxifloxacin Hcl | 117 | $3,312 |
| Ketorolac Tromethamine | 133 | $3,209 |
| Latanoprost | 200 | $1,339 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 103 | $1,223 |
| Brimonidine Tartrate | 33 | $1,186 |
| Ofloxacin | 73 | $1,049 |
| ErythromycinErythromycin Base | 68 | $970 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 87 | $887 |
| Timolol Maleate | 34 | $726 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Phoenix
- Pravin DugelPhoenix$176K
- Nishi ShahPhoenix$92K
- Karim JamalPhoenix$72K
- Benjamin HellerPhoenix$41K
- Neal PalejwalaPhoenix$33K
- Joshua DuncanPhoenix$30K
- Sachin MehtaPhoenix$23K
- Daniel ChurginPhoenix$15K
- John CasonPhoenix$14K
- Sujit IttyPhoenix$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.